Genmab — Oktober 2019

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Morgen nyheder: https://www.proinvestor.com/chathistory/58/chat nyheder

[transalp]

Go morgen. og tak til helge og co, for at udvide proinvestor..

[Helge_LarsenPI-redaktør]

Selv tak. Udvidelsen er naturlig, nu hvor behovet er der.

[E_L]

this DaraSC DuoBody combination now also on EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000330-19/ES
Should we count this as 1 or as 2 duobodies? (under the program Janssen will collaborate on the research of up to 10 DuoBody programs)

[Sukkeralf]

Do you mean IV and SC - this should count as one I would say

[Sukkeralf]

Its the target combination and not the delivery that counts

[Sukkeralf]

Hope to see data from this one at ASH

[E_L]

no, i thought 1 being Dara Anti-BCMAxCD3 and the second Dara Anti-GPRC5DxCD3

[E_L]

(about IV and SC; i saw yesterday that AbbVie is now using "Administered by subcutaneous injection (preferred) OR intravenously (IV)" in the Venetoclax trial it just reopened again (and wehre they added a few arms)) https://clinicaltrials.gov/ct2/history/NCT03314181?A=15&B=16&C=merged#StudyPageTop

[Sukkeralf]

Yes thats 2 duobodies

[E_L]

ok. if i count correct we now have 8 then. 2 to go. Will be interesting to see what happens when all 10 are used, will they
enlarge the program at some point.

[Sukkeralf]

Remember Janssen has the right to 20 DuoBody programs

[Sukkeralf]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-expansion-duobody-platform-collaboration/

[peter12]

Det er lidt af en milestone

[peter12]

Men det er efter 20 programmer ....

[Sukkeralf]

Fra årsregnskabet: As of December 31, 2018, Janssen had exercised 14
licenses under this collaboration. No further options remain
for use by Janssen.

[E_L]

ok, thanks for updating me here

[E_L]

so the difference between the 14 and 20? maybe to do with an expiration time?

[Sukkeralf]

Im not sure how to understand that last sentence "No further options remain for use by Janssen".